|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US4326525A
(en)
|
1980-10-14 |
1982-04-27 |
Alza Corporation |
Osmotic device that improves delivery properties of agent in situ
|
|
US5364620A
(en)
|
1983-12-22 |
1994-11-15 |
Elan Corporation, Plc |
Controlled absorption diltiazem formulation for once daily administration
|
|
US5023252A
(en)
|
1985-12-04 |
1991-06-11 |
Conrex Pharmaceutical Corporation |
Transdermal and trans-membrane delivery of drugs
|
|
US5001139A
(en)
|
1987-06-12 |
1991-03-19 |
American Cyanamid Company |
Enchancers for the transdermal flux of nivadipine
|
|
US4992445A
(en)
|
1987-06-12 |
1991-02-12 |
American Cyanamid Co. |
Transdermal delivery of pharmaceuticals
|
|
US4902514A
(en)
|
1988-07-21 |
1990-02-20 |
Alza Corporation |
Dosage form for administering nilvadipine for treating cardiovascular symptoms
|
|
GB9718833D0
(en)
|
1997-09-04 |
1997-11-12 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US6329412B1
(en)
|
1997-11-04 |
2001-12-11 |
Pfizer Inc |
Bisamidine compounds as antiproliferative agents
|
|
US7825154B2
(en)
|
2005-08-12 |
2010-11-02 |
The United States Of America As Represented By The Secretary Of The Army |
Small molecule inhibitors of botulinum neurotoxins
|
|
RU2385865C2
(ru)
|
2005-08-15 |
2010-04-10 |
Айрм Ллк |
Соединения и композиции в качестве миметиков тро
|
|
EP1779848A1
(en)
|
2005-10-28 |
2007-05-02 |
Nikem Research S.R.L. |
V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
|
|
EP2044083A1
(en)
|
2006-07-14 |
2009-04-08 |
Genelabs Technologies, Inc. |
Antiviral agents
|
|
CN101583598B
(zh)
|
2007-01-15 |
2012-09-12 |
参天制药株式会社 |
具有IκB激酶β抑制活性的新型吲哚衍生物
|
|
HUE029188T2
(en)
|
2007-03-12 |
2017-03-28 |
Ym Biosciences Australia Pty |
Phenylamino-pyrimidine compounds and their use
|
|
WO2008152471A1
(en)
|
2007-06-12 |
2008-12-18 |
Coley Pharmaceutical Group, Inc. |
Quinazoline derivative useful as toll-like receptor antagonist
|
|
US8354400B2
(en)
|
2008-09-26 |
2013-01-15 |
Eisai R&D Co., Ltd. |
Benzoxazole compounds and methods of use
|
|
WO2011050245A1
(en)
|
2009-10-23 |
2011-04-28 |
Yangbo Feng |
Bicyclic heteroaryls as kinase inhibitors
|
|
AU2012262021B2
(en)
|
2011-06-01 |
2016-07-28 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
|
BR112013030894A2
(pt)
|
2011-06-01 |
2016-08-16 |
Janus Biotherapeutics Inc |
moduladores do sistema imune
|
|
WO2013052263A2
(en)
|
2011-09-16 |
2013-04-11 |
Microbiotix, Inc. |
Antifungal compounds
|
|
CA2850932A1
(en)
|
2011-10-04 |
2013-04-11 |
Janus Biotherapeutics, Inc. |
Novel imidazole quinoline-based immune system modulators
|
|
JO3407B1
(ar)
|
2012-05-31 |
2019-10-20 |
Eisai R&D Man Co Ltd |
مركبات رباعي هيدرو بيرازولو بيريميدين
|
|
KR101452579B1
(ko)
|
2012-08-17 |
2014-10-21 |
주식회사 두산 |
신규 화합물 및 이를 포함하는 유기 전계 발광 소자
|
|
ES2670550T3
(es)
|
2013-10-14 |
2018-05-30 |
Eisai R&D Management Co., Ltd. |
Derivados de quinolina selectivamente sustituidos
|
|
KR101823488B1
(ko)
|
2013-10-14 |
2018-01-30 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
선택적으로 치환된 퀴놀린 화합물
|
|
US20170275287A1
(en)
|
2014-08-22 |
2017-09-28 |
Janus Biotherapeutics, Inc. |
Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
|
|
LT3277677T
(lt)
|
2015-03-30 |
2021-05-25 |
Mission Therapeutics Limited |
1-ciano-pirolidino junginiai kaip usp30 inhibitoriai
|
|
WO2017075694A1
(en)
|
2015-11-04 |
2017-05-11 |
Simon Fraser University |
Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor
|
|
MX2021006804A
(es)
|
2015-12-17 |
2023-01-13 |
Merck Patent Gmbh |
Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
|
|
KR102706837B1
(ko)
|
2016-04-15 |
2024-09-19 |
캔써 리서치 테크놀로지 리미티드 |
Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
|
|
TWI746545B
(zh)
|
2016-04-26 |
2021-11-21 |
日商大日本住友製藥股份有限公司 |
經取代嘌呤衍生物
|
|
US10071079B2
(en)
|
2016-06-29 |
2018-09-11 |
Bristol-Myers Squibb Company |
[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
|
|
CN109715617B
(zh)
|
2016-07-30 |
2022-04-19 |
百时美施贵宝公司 |
作为tlr7、tlr8或tlr9抑制剂的二甲氧基苯基取代的吲哚化合物
|
|
AU2017311047B2
(en)
|
2016-08-08 |
2021-07-22 |
Merck Patent Gmbh |
TLR7/8 antagonists and uses thereof
|
|
ES2902504T3
(es)
|
2016-09-09 |
2022-03-28 |
Bristol Myers Squibb Co |
Compuestos de indol sustituidos con piridilo
|
|
EP4059934B1
(en)
|
2016-09-09 |
2026-07-29 |
Novartis AG |
Compounds and compositions as inhibitors of endosomal toll-like receptors
|
|
WO2019018354A1
(en)
|
2017-07-18 |
2019-01-24 |
Merck Patent Gmbh |
ANTAGONISTS OF TLR7 / 8 AND USES THEREOF
|
|
CN110997670B
(zh)
|
2017-08-04 |
2022-11-01 |
百时美施贵宝公司 |
[1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
|
|
EP3661926B1
(en)
|
2017-08-04 |
2022-02-23 |
Bristol-Myers Squibb Company |
Substituted indole compounds useful as inhibitors of tlr7/8/9
|
|
JP2021035910A
(ja)
|
2017-11-01 |
2021-03-04 |
大日本住友製薬株式会社 |
置換プリン化合物
|
|
AU2018364807B2
(en)
|
2017-11-08 |
2022-05-19 |
Council Of Scientific & Industrial Research |
Purine based compounds as toll-like receptor 9 antagonist
|
|
CN111448190B
(zh)
|
2017-11-14 |
2023-09-26 |
百时美施贵宝公司 |
取代的吲哚化合物
|
|
US12030878B2
(en)
|
2017-12-15 |
2024-07-09 |
Bristol-Myers Squibb Company |
Substituted indole ether compounds
|
|
MX2020006168A
(es)
|
2017-12-18 |
2020-08-13 |
Bristol Myers Squibb Co |
Compuestos de 4-azaindol.
|
|
EP3728253B1
(en)
|
2017-12-19 |
2024-03-27 |
Bristol-Myers Squibb Company |
6-azaindole compounds
|
|
EA202091474A1
(ru)
|
2017-12-19 |
2020-11-18 |
Бристол-Маерс Сквибб Компани |
Замещенные индольные соединения, применимые в качестве ингибиторов tlr
|
|
WO2019126081A1
(en)
|
2017-12-19 |
2019-06-27 |
Bristol-Myers Squibb Company |
Amide substituted indole compounds useful as tlr inhibitors
|
|
JP2021506862A
(ja)
|
2017-12-19 |
2021-02-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
Ｔｌｒ７／８アンタゴニストおよびそれらの使用
|
|
JP7287967B2
(ja)
|
2017-12-20 |
2023-06-06 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔｌｒ阻害剤として有効なアミノインドール化合物
|
|
KR102730859B1
(ko)
|
2017-12-20 |
2024-11-15 |
브리스톨-마이어스 스큅 컴퍼니 |
아릴 및 헤테로아릴 치환된 인돌 화합물
|
|
EA202091530A1
(ru)
|
2017-12-20 |
2020-09-14 |
Бристол-Маерс Сквибб Компани |
Диазаиндольные соединения
|
|
JP2021507889A
(ja)
|
2017-12-22 |
2021-02-25 |
ノバルティス アーゲー |
ピラゾロピペリジン誘導体の新規な使用
|
|
CN110194770B
(zh)
*
|
2018-02-26 |
2022-08-09 |
药捷安康(南京)科技股份有限公司 |
肽酰精氨酸脱亚胺酶抑制剂及其用途
|
|
WO2019220390A1
(en)
|
2018-05-18 |
2019-11-21 |
Novartis Ag |
Crystalline forms of a tlr7/tlr8 inhibitor
|
|
SG11202100818RA
(en)
|
2018-07-31 |
2021-02-25 |
Merck Patent Gmbh |
Tlr7/8 antagonists and uses thereof
|
|
ES2963696T3
(es)
|
2018-10-24 |
2024-04-01 |
Bristol Myers Squibb Co |
Compuestos diméricos de indol sustituidos
|
|
US12172995B2
(en)
|
2018-10-24 |
2024-12-24 |
Bristol-Myers Squibb Company |
Substituted indole and indazole compounds
|
|
US20220213099A1
(en)
|
2019-05-07 |
2022-07-07 |
Bristol-Myers Squibb Company |
Prodrug compounds
|
|
KR102904576B1
(ko)
|
2019-05-09 |
2025-12-24 |
브리스톨-마이어스 스큅 컴퍼니 |
치환된 벤즈이미다졸론 화합물
|
|
EP3972636A4
(en)
|
2019-05-23 |
2023-08-02 |
The University Of Montana |
VACCINE ADJUVANTS BASED ON TLR RECEPTOR LIGANDS
|
|
TW202115083A
(zh)
*
|
2019-09-27 |
2021-04-16 |
大陸商南京藥捷安康生物科技有限公司 |
肽醯精胺酸脫亞胺酶抑制劑及其用途
|
|
WO2021067326A1
(en)
*
|
2019-10-01 |
2021-04-08 |
Bristol-Myers Squibb Company |
Substituted bicyclic heteroaryl compounds
|
|
CN114829350B
(zh)
|
2019-10-04 |
2024-05-28 |
百时美施贵宝公司 |
经取代的咔唑化合物
|
|
JP7652772B2
(ja)
|
2019-11-01 |
2025-03-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
置換ピラゾール化合物
|
|
US20240024308A1
(en)
|
2020-05-14 |
2024-01-25 |
Merck Healthcare Kgaa |
Tlr7/8 antagonists for the treatment of coronavirus infections
|
|
JP7751597B2
(ja)
|
2020-06-11 |
2025-10-08 |
ブリストル－マイヤーズ スクイブ カンパニー |
皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるｔｌｒ７阻害剤
|
|
KR20230027212A
(ko)
|
2020-06-22 |
2023-02-27 |
브리스톨-마이어스 스큅 컴퍼니 |
류마티스 관절염의 치료 방법
|
|
WO2022022489A1
(zh)
|
2020-07-27 |
2022-02-03 |
江苏恒瑞医药股份有限公司 |
吲哚稠环类衍生物、其制备方法及其在医药上的应用
|
|
CN114075219B
(zh)
|
2020-08-14 |
2023-11-14 |
江苏恒瑞医药股份有限公司 |
喹啉稠环类衍生物、其制备方法及其在医药上的应用
|
|
CN114075212B
(zh)
|
2020-08-14 |
2023-05-12 |
江苏恒瑞医药股份有限公司 |
稠合三环类衍生物、其制备方法及其在医药上的应用
|
|
EP4200015B1
(en)
|
2020-08-19 |
2026-04-29 |
Bristol-Myers Squibb Company |
Substituted heteroaryl compounds useful as inhibitors of tlr9
|
|
EP4253387A4
(en)
|
2020-11-26 |
2024-05-15 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Fused tricyclic compound, preparation method therefor and application thereof in medicine
|
|
EP4267560A1
(en)
|
2020-12-22 |
2023-11-01 |
Gilead Sciences, Inc. |
6-substituted indole compounds
|
|
EP4267559A1
(en)
|
2020-12-22 |
2023-11-01 |
Gilead Sciences, Inc. |
Substituted indole compounds
|